Nykode Therapeutics is a Norwegian biopharmaceutical company dedicated to developing new immunotherapy to combat cancer, infectious diseases and autoimmune conditions.
The company is developing groundbreaking, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Nykode’s unique modular technology platform is designed so that the active substances are directed to those cells in the body that are optimal for initiating fast, strong and long-lasting immune responses. The overall goal is to reduce the impact of disease on people’s lives.
Location: Norway, Oslo
Employees: 51-200
Founded date: 2007
Investors 4
| Date | Name | Website |
| - | TD Veen | tdveen.no |
| - | Kvantia | kvantia.no |
| - | p53 | p53.no |
| - | Sarsia | sarsia.com |
Mentions in press and media 3
| Date | Title | Description | Source |
| 11.02.2022 | Nykode Therapeutics announces completion of patient enrollme... | Nykode Therapeutics has reached the enrollment target of 50 patients in its VB C-02 trial for the tr... | marketscre... |
| 28.12.2021 | Nykode Therapeutics announces first subject dosed with its T... | First subject dosed with Nykode Therapeutics’ T cell focused SARS-CoV-2 vaccine candidate. This is p... | marketscre... |
| 15.12.2021 | New chairman at Nykode Therapeutics as the Company enters a ... | o Martin Nicklasson proposed as new chairman at Nykode Therapeutics as the Company enters a new sta... | marketscre... |